Sun Pharma Advanced Research Company Limited

NSEI:SPARC Stock Report

Market Cap: ₹66.4b

Sun Pharma Advanced Research Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sun Pharma Advanced Research.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth17.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans

Jan 17
Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans

Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't

Nov 14
Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't

Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?

Sep 05
Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?

Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation

Jun 27
Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation

Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

Nov 23
Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%

Feb 08
If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%

Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

Dec 14
Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sun Pharma Advanced Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:SPARC - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024601-4,087-4,635-4,384N/A
6/30/2024684-3,878N/AN/AN/A
3/31/2024755-3,872-4,557-4,292N/A
12/31/20231,067-3,634N/AN/AN/A
9/30/20232,239-2,536-1,712-1,589N/A
6/30/20232,343-2,356N/AN/AN/A
3/31/20232,388-2,226-845-691N/A
12/31/20222,163-2,116N/AN/AN/A
9/30/20221,474-2,376-2,148-1,799N/A
6/30/20221,437-2,244N/AN/AN/A
3/31/20221,372-2,034-2,409-2,082N/A
12/31/20211,401-1,891N/AN/AN/A
9/30/2021997-2,408-2,766-2,677N/A
6/30/2021895-2,692N/AN/AN/A
3/31/20212,530-1,511-1,579-1,519N/A
12/31/20202,476-1,940N/AN/AN/A
9/30/20202,454-1,819-1,243-812N/A
6/30/20202,450-1,615N/AN/AN/A
3/31/2020768-3,124-2,648-2,108N/A
12/31/20191,389-2,222N/AN/AN/A
9/30/20191,392-2,357-2,528-2,289N/A
6/30/20191,834-1,751N/AN/AN/A
3/31/20191,829-1,454-1,849-1,719N/A
12/31/20181,181-1,336N/AN/AN/A
9/30/20181,177-1,226N/AN/AN/A
6/30/2018717-1,826N/AN/AN/A
3/31/2018783-1,970N/A-1,828N/A
12/31/2017998-2,326N/AN/AN/A
9/30/20171,034-2,405N/AN/AN/A
6/30/20171,829-1,630N/AN/AN/A
3/31/20171,810-1,190N/A-1,280N/A
12/31/20161,827-976N/AN/AN/A
9/30/20161,932-723N/AN/AN/A
6/30/20161,415-1,048N/AN/AN/A
3/31/20161,613-700N/A-442N/A
12/31/20151,628-698N/AN/AN/A
9/30/20151,605-477N/AN/AN/A
6/30/20151,633-314N/AN/AN/A
3/31/20151,557-395N/A-412N/A
12/31/20141,556-326N/AN/AN/A
9/30/20141,873173N/AN/AN/A
6/30/20141,672111N/AN/AN/A
3/31/20141,670303N/A369N/A
12/31/20131,963769N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SPARC's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if SPARC's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if SPARC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SPARC's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if SPARC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPARC's Return on Equity is forecast to be high in 3 years time


Discover growth companies